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ORIGINAL ARTICLE
Introduction: Management of Stage III non–small-cell lung cancer 
(NSCLC) involves surgery, radiotherapy (RT), chemotherapy, and 
best supportive care. The aims were to describe the patterns of treat-
ment in a population-based cohort of patients, and compare utiliza-
tion of RT and chemotherapy to model estimates of need.
Methods: Patients diagnosed with Stage III NSCLC between 
January 1, 2000, to December 31, 2007, were identified from the 
British Columbia Cancer Agency database. Patients who had prior 
or concomitant malignancy were excluded. Patient demographics, 
tumor characteristics, and initial treatment were extracted. Survival 
data were derived from the British Columbia Vital Statistics Death 
Listings.
Results: 2365 patients with Stage III NSCLC were referred, of which 
212 patients were excluded, leaving 2153 patients in the study pop-
ulation. Median age was 69 years. Disease stage was IIIA in 49% 
and IIIB in 51%. Histologies were squamous-cell carcinoma (31%), 
adenocarcinoma (27%), NSCLC not otherwise specified (31%), and 
other pathology (11%). Initial treatment included surgery in 12%, RT 
in 78%, and chemotherapy in 31%. Predicted RT utilization was 77% 
to 87% and chemotherapy 78%. From 2000 to 2007, curative-intent 
treatment increased from 21% to 35%, chemoradiotherapy from 8% 
to 18.6%, and concurrent chemoradiotherapy from 5.1% to 17.6%. 
Median survival was 30 months for patients who had curative sur-
gery, 21 months for curative RT, 8 months for palliative treatment, 
and 5 months for best supportive care (p < 0.001).
Conclusion: RT utilization was similar to that predicted by models 
whereas chemotherapy utilization was less. During the study period, 
the proportion of patients receiving curative chemoradiotherapy dou-
bled and of those receiving concurrent chemoradiotherapy trebled.
Key Words: Chemotherapy, Non–small-cell lung cancer, Physicians 
practice patterns, Radiotherapy, Surgery.
(J Thorac Oncol. 2012;7: 1155–1163)
Stage III non–small-cell lung cancer (NSCLC) as defined by Union for International Cancer Control TNM 
Classification 6th edition,1 comprises a heterogeneous popu-
lation of patients. The basis of staging can be either clinical 
or pathological following surgery. Disease extent varies from 
potentially curable small-volume locoregional disease to dis-
ease that is incurable because of its size, location, or pleural 
involvement. Management options range from any combina-
tion of surgery, radiotherapy (RT), and chemotherapy to best 
supportive care (BSC).
Evidence-based guidelines have been used to derive models 
of optimal utilization of RT and chemotherapy for patients with 
lung cancer.2–5 These models use population characteristics, stage, 
and Eastern Cooperative Oncology Group (ECOG) performance 
status to determine whether patients would benefit from treat-
ment. Estimates of optimal RT utilization at diagnosis in Stage III 
NSCLC range from 84% to 92%, and of chemotherapy is 88%.2–4
However, guideline-based treatments are not applicable 
to many patients with Stage III NSCLC.6 Patients are typi-
cally elderly with comorbidities, a group poorly represented 
in clinical trials, which results in limited high-level evidence 
on which to base treatment for many patients.7,8 Curative treat-
ment usually requires multiple modalities,9,10 which may be 
difficult to deliver in such patients.
In the general population of Stage III NSCLC patients, 
it is not clear what proportion is eligible for guideline-based 
treatment, in particular curative treatment. The aims of this 
study were to describe the patterns of treatment in a cohort of 
patients with Stage III NSCLC, define the proportion treated 
with curative intent, and compare the utilization of chemo-
therapy and RT to that predicted by published models.
MATERIALS AND METHODS
The British Columbia Cancer Agency (BCCA) is a pro-
vincial organization, with five regional cancer centers (four 
operating during the study era), which provides all RT, and 
manages the budget for all antineoplastic systemic therapy for 
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cancer patients diagnosed in British Columbia, Canada (popu-
lation 4.5 million). Demographic data, tumor characteristics, 
treatment, and overall-survival outcome information for all 
patients with lung cancer referred to the BCCA for consultation 
are collected prospectively. Provincial management guidelines 
were available and regularly updated by the province-wide 
BCCA Lung Tumour Group comprising radiation oncologists, 
medical oncologists, respiratory physicians, and surgeons 
treating patients with lung cancers at the BCCA (http://www.
bccancer.bc.ca/HPI/CancerManagementGuidelines/Lung/
start.htm). The BCCA also oversees the BC Cancer Registry, 
which houses demographic and pathologic information for all 
patients diagnosed with cancer in British Columbia.
All patients newly diagnosed with clinical or pathologic 
Stage III NSCLC between January 1, 2000 to December 31, 
2007 were identified from this database. Patients had to have 
sufficient staging to determine the tumor, node, metastasis 
(TNM) stage. Stage groupings were based on the Union for 
International Cancer Control TNM Classification 6th edition.1 
Patients with a pathologically confirmed diagnosis (identified 
by ICD-0 histology codes 8000.3, 8010.3, 8012.3, 8013.3, 
8014.3, 8020.3, 8021.3, 8046.3, 8070.3, 8071.3, 8072.3, 
8073.3, 8074.3, 8130.2, 8083.3, 8140.3, 8250.3, 8252.3, 
8253.3, 8255.3, 8260.3, 8480.3, 8481.3, 8490.3, 8550.3, and 
8560.3) were included. Patients with concomitant malignan-
cies diagnosed within 6 months of lung cancer diagnosis and 
those with a prior history of malignancy, other than non-mel-
anomatous  skin cancer and carcinoma-in-situ of the cervix, 
within 5 years preceding lung cancer diagnosis were excluded. 
Patients with a prior history of lung cancer or multifocal lung 
cancers were also excluded.
Details on patient demographics, tumor characteristics, 
and the first course of treatment (surgery, RT, chemotherapy, 
and BSC) were extracted. Initial treatment was coded as a 
variable within the BCCA database (as opposed to treatment 
for progression or recurrence). We also limited our definition 
of initial treatment to that which commenced within 6 months 
of diagnosis unless it was a planned course of sequential treat-
ment modalities. For patients receiving RT as the primary treat-
ment, we assumed curative intent if the minimum dose was 
50 Gy. This dose was chosen to include patients who were 
treated with hypofractionated regimens such as 50 Gy in 20 
fractions. For those receiving RT before or after surgery, coded 
as part of the initial treatment, this was assumed to be treat-
ment with curative intent regardless of dose. Curative-intent 
chemotherapy was defined as that which was given immedi-
ately before or after surgical resection or immediately before 
or after, or concurrently with curative-dose RT. Treatment 
given for progressive or recurrent disease was not included. 
Survival data within the BCCA databases were derived from 
the British Columbia Vital Statistics Death Listings. All 
records were censored on  June 30, 2010. Ethics approval was 
obtained from the BCCA Research Ethics Board.
Statistical analysis was performed using SPSS 
V18.11 Comparisons were made using Pearson’s χ2 tests. 
Multivariable analysis was performed using Cox regression. 
Survival analysis was performed using Kaplan-Meier curves 
and comparisons were made using the log-rank test. A p value 
of < 0.05 was interpreted as significant. The median follow-up 
of patients was 37 months, as calculated from the survival of 
patients alive at last follow-up.
RESULTS
Between January 1, 2000 and December 31, 2007, the 
British Columbia Cancer Registry identified 20,707 British 
Columbia residents with a new diagnosis of lung cancer. Of 
these, 13,131 (63%) were referred to BCCA for management 
and  2365 were patients with confirmed Stage III NSCLC. 
Two hundred and twelve patients were excluded because of 
concomitant malignancy (n = 55), prior history of malignancy 
(n = 79) or prior or synchronous lung cancer (n = 78). Two 
thousand one hundred and fifty-three patients formed the 
study population.
TABLE 1. Patient and Tumor Characteristics of  the Study 
Cohort
TOTAL
N %
2153 100
Sex
 Male 1183 54.9
 Female 970 45.1
Age (yrs)
 <50 145 6.7
 50–64 647 30.1
 65–79 1085 50.4
 80+ 276 12.8
ECOG PS
 ECOG 0–1 927 43.1
 ECOG 2 442 20.5
 ECOG 3–4 392 18.2
 Unknown 392 18.2
Diagnosis period
 2000–2003 1015 47.1
 2004–2007 1138 52.9
Stage
 Pathological IIIAa 160 7.4
 Clinical IIIA 904 42.0
 Pathological IIIBa 54 2.5
 Clinical IIIB 1035 48.1
Laterality
 Right 1253 58.2
 Left 887 41.2
 Unknownb 13 0.6
Histology
 Squamous-cell carcinoma 661 30.7
 Adenocarcinoma 589 27.4
 Large-cell carcinoma 106 4.9
 NSCLC NOS 668 31.0
 NSCLC other 129 6.0
ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, 
Non–small-cell lung cancer; NOS, not otherwise specified.
aPathological staging refers to staging based on surgical resection.
bTumors involving trachea.
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Patient and tumor characteristics are shown in 
Table 1. The median age was 69 years (33–94). The major-
ity of patients had good performance status (PS). Similar 
proportions had Stage IIIA and IIIB disease. We could not 
determine which patients with Stage IIIB cancers had pleu-
ral effusions, however, 59 (5%) underwent pleurodesis. The 
most common pathologies were NSCLC not otherwise speci-
fied and squamous-cell carcinoma. Eighteen percent of the 
patients had unknown ECOG PS. These patients were similar 
to those with known ECOG PS except for  17% aged 80 years 
or older compared to 12% of those with known ECOG PS (p 
= 0.005).
There were no significant differences in the population 
distribution according to sex, age, ECOG PS, and stage over the 
8 years of the study. There were some differences in pathological 
classification over time. From 2000 to 2007, the proportion of 
squamous-cell carcinoma decreased from 30% to 24%, adeno-
carcinoma from 35% to 24%, and large-cell carcinoma from 
14% to 3% (p < 0.0001). Conversely, NSCLC not otherwise 
specified increased from 1% in 2000 to 47% in 2007.
Surgery
Two hundred and fifty patients (12%) received sur-
gery as part of their initial treatment. Of these, 96 (39%) had 
surgery alone, 36 (14%) had neoadjuvant treatment before 
surgery, and 118 (47%) had surgery and adjuvant therapy 
(Table 2). Lobectomy was the most frequent operation 
performed (n = 153.61%), followed by pneumonectomy 
(n = 81.33%), and segmental resection (n = 16.6%).
Radiotherapy
RT was part of initial treatment in 1681 patients (78%). 
(Table 2) Curative RT was only given to 16.9% of the patients. 
Of the 363 patients who received curative RT, the median 
dose was 60 Gy (n = 173, 47.6%). Doses higher than 60 Gy 
(n = 108, 29.8%) were occasionally used, most commonly 
66 Gy (n = 46, 12.7%). These doses were usually delivered 
in 2 Gy fractions. Other common fractionation schemes were 
55 Gy in 20 fractions (n = 20, 5.5%) and 50 Gy in 20 fractions 
(n = 15, 4.1%).
Palliative RT alone was the most common overall treat-
ment in this cohort (n = 1228, 57%). The median RT dose was 
20 Gy in five fractions (n = 526, 42.8%). Other common doses 
were 30 Gy in 10 fractions (n = 257, 20.9%), 8 or 10 Gy in 
1 fraction (n = 84, 6.8%), and 40 Gy in 15 fractions (n = 35, 
2.9%). Five patients received endobronchial brachytherapy 
alone as palliative treatment.
The use of preoperative and postoperative RT was 
uncommon (n = 90, 4.2%). The most frequent doses were 50 
Gy in 20 to 25 fractions (n = 31, 34.4%) and 45 Gy in 20 to 25 
fractions (n = 27, 30%).
Chemotherapy
Six hundred and sixty-eight patients (31%) received 
chemotherapy as part of their initial treatment (Table 2). 
Similar proportions received palliative chemotherapy 
(n = 279, 12.9%) and chemotherapy combined with cura-
tive RT (n = 287, 13.3%). The most common palliative che-
motherapy regimens were cisplatin and etoposide (n = 91, 
32.6%), cisplatin and vinorelbine (n = 87 31.2%) and cispla-
tin and gemcitabine (n = 30, 10.8%). A cisplatin–etoposide 
combination was used in 237 patients (82.6%) treated with 
curative RT. Preoperative and postoperative chemotherapy 
was infrequently used (n = 102, 4.7%). Cisplatin–etoposide 
(n = 45) and cisplatin–vinorelbine (n = 40) were the most 
frequent regimens in this setting.
TABLE 2. Initial Treatment of Study Cohort – n (% of Stage)
Treatment Stage IIIA n = 1064 Stage IIIB n = 1089 Total n = 2153
Surgery alone 62 (5.8) 34 (3.1) 96 (4.5)
Surgery + adjuvant chemotherapy 49 (4.6) 12 (1.1) 61 (2.8)
Surgery + adjuvant radiotherapy 43 (4.1) 8 (0.7) 51 (2.3)
Surgery + adjuvant chemotherapy and radiotherapy 6 (0.6) 0 (0) 6 (0.3)
Neoadjuvant chemotherapy + surgery 1 (0.1) 2 (0.2) 3 (0.1)
Neoadjuvant radiotherapy + surgery 1 (0.1) 0 (0) 1 (0)
Neoadjuvant chemotherapy + radiotherapy + surgery 22 (2.1) 8 (0.7) 30 (1.4)
Neoadjuvant radiotherapy + surgery + adjuvant chemotherapy 1 (0.1) 0 (0) 1 (0)
Neoadjuvant chemotherapy + surgery + adjuvant radiotherapy 1 (0.1) 0 (0) 1 (0)
TOTAL CURATIVE SURGERY 186 (17.5) 64 (5.9) 250 (11.6)
Curative radiotherapy + concurrent chemotherapy 161 (15.1) 104 (9.5) 265 (12.3)
Neoadjuvant chemotherapy + curative radiotherapy 15 (1.4) 7 (0.6) 22 (1)
Curative radiotherapy alone 43 (4.0) 33 (3.0) 76 (3.5)
TOTAL CURATIVE RADIOTHERAPY 219 (20.5) 144 (13.2) 363 (16.9)
Palliative radiotherapy + palliative chemotherapy 69 (6.5) 124 (11.4) 193 (9)
Palliative radiotherapy alone 471 (44.3) 564 (51.7) 1035 (48)
Palliative chemotherapy alone 17 (1.6) 69 (6.4) 86 (4)
TOTAL PALLIATIVE TREATMENT 557 (52.4) 757 (69.6) 1314 (61.0)
No active treatment 102 (9.6) 124 (11.4) 226 (10.5)
TOTAL BEST SUPPORTIVE CARE 102 (9.6) 124 (11.4) 226 (10.5)
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Treatment Combinations
Treatment was divided into four groups for further anal-
ysis (Table 3). The median age of patients undergoing curative 
treatment was significantly lower than of those treated pal-
liatively. As would be expected, curative treatment was more 
commonly given to patients with Stage IIIA disease and those 
of good PS. However, even in patients who were ECOG zero 
to two, only 35.2% received curative treatment. There were 
some differences in the treatment of different pathological 
subtypes with a greater proportion of patients with adenocar-
cinoma undergoing surgery. The use of curative RT increased 
significantly in the second half of the study period with a cor-
responding reduction in palliative treatment.
Figure 1 shows changes in treatment over time. The use 
of curative treatment increased over time from 21.1% in 2000 
to 35% in 2007. This was largely because of  the increased 
utilization of curative chemoradiotherapy, which increased 
from 8% in 2000 to 18.6% in 2007. The use of neoadjuvant 
chemotherapy before RT decreased from 2.9% to 1%  and the 
use of concurrent chemoradiotherapy increased from 5.1% to 
17.6% over the same time period. Use of curative RT alone 
showed minimal change from 2.9% in 2000 to 3.9% in 2007. 
The use of palliative chemotherapy either alone or with pal-
liative RT decreased from 16.7% in 2000 to 10.6% in 2007. 
The proportions receiving surgery and BSC remained similar 
over the years.
In patients with Stage IIIA NSCLC, the use of curative 
surgery increased from 14.7% to 18.3% and that of curative 
chemoradiotherapy from 11.6% to 25.5% from 2000 to 2007. 
For patients with Stage IIIB NSCLC the use of surgery was 
similar over the years, being 6.2% in 2000 and 7% in 2007 
whereas curative chemoradiotherapy increased from 4.8% to 
12% over this time period.
Comparison With Models of Evidence-Based 
Utilization
The distribution of stage and PS was inserted into the 
RT models published by Delaney et al.2 and Tyldesley et al.3 to 
estimate the optimal (initial) utilization of RT in this cohort. 
If there were factors influencing the recommendation for RT 
that were not documented in this cohort (such as presence of 
symptoms, positive margins, and patient preferences), then 
these proportions were taken directly from the model (Fig. 2). 
TABLE 3. Distribution of Prognostic Factors Among Initial Treatment Groups n (% of Variable)
Curative Surgery 
n = 250
Curative 
Radiotherapy  
n = 363
Palliative 
Treatment  
n = 1314
BSC 
n = 226 p
Age
 M edian in yrs  
(range)
65 (37–84) 63 (40–92) 71 (33–94) 75 (36–92) <0.001
Stage
 IIIA 186 (17.5) 219 (20.6) 557 (52.3) 102 (9.6) <0.001
 IIIB 64 (5.9) 144 (13.2) 757 (69.5) 124 (11.4)
Pathology
 SCC 65 (9.8) 121 (18.3) 415 (62.8) 60 (9.1) <0.001
 Adenocarcinoma 126 (21.4) 96 (16.3) 305 (51.8) 62 (10.5)
 LCC 12 (11.3) 10 (9.4) 68 (64.2) 16 (15.1)
 Other 47 (5.9) 136 (17.1) 526 (66) 88 (11)
ECOG PS
 0–2 176 (12.9) 305 (22.3) 754 (55.1) 134 (9.8) <0.001
 3–4 17 (4.3) 10 (2.6) 306 (78.1) 59 (15.1)
 Unknown 57 (14.5) 48 (12.2) 254 (64.8) 33 (8.4)
Period of diagnosis
 2000–2003 106 (10.4) 133 (13.1) 669 (65.9) 107 (10.5) <0.001
 2004–2007 144 (12.7) 230 (20.2) 645 (56.7) 119 (10.5)
BSC, best supportive care; SCC, squamous-cell carcinoma; LCC, large-cell carcinoma; ECOG PS, Eastern Cooperative Oncology 
Group performance status.
FIGURE 1. Treatment groups for study cohort by year of 
diagnosis.
1159Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 7, July 2012 Patterns of Treatment in Stage III NSCLC
FIGURE 2. Study population applied to radiotherapy utilization model published by Tyldesley et al.3
FIGURE 3. Study population applied to chemotherapy utilization model published by Jacob et al.4
The optimal utilization of RT was predicted to be 77% and 
87% on the basis of  Tyldesley’s model  and Delaney’s model, 
respectively. The actual RT utilization of 78% is similar to 
the former estimate. The main difference between the models 
is that Tyldesley accounts for Stage III patients who have a 
preference for BSC over RT whereas Delaney’s model pre-
sumes that all patients who have an indication for RT choose 
to receive it.
For chemotherapy, the population characteristics were 
entered into a chemotherapy model published by Jacob et al.4 
(Fig. 3). From this, the optimal utilization of chemotherapy 
at diagnosis was predicted to be 77.7%. The chemotherapy 
utilization of 31% in this study is well less than this. This 
model, however, assumes that all patients were fit enough to 
receive chemotherapy, and does not take patient preferences 
into account.
Logistic regression analysis was performed to inves-
tigate factors that predicted for the use of chemotherapy. 
Patients with adenocarcinoma histology (hazard ratio 
[HR] = 1.50, 95% confidence interval [CI] 1.13–2.00, p = 
0.005), and those diagnosed from 2004 onward (HR 2.36,95% 
CI 1.90–2.96, p < 0.0001) were more likely to receive che-
motherapy. Increasing age was associated with less frequent 
use of chemotherapy with patients (50–64 years HR = 0.66; 
65–79 years HR = 0.15; ≥ 80 years HR = 0.10 relative to <50-
year olds) as was poor PS (HR = 0.11, 95% CI 0.07–0.17, 
p < 0.0001).
Overall Survival
The median overall survival for all patients was 
11 months (95% CI 10.4–11.6 months). The 1-year and 5-year 
survivals were 47% and 9%, respectively. As 94% of deaths 
were from lung cancer, lung cancer specific survival was 
not separately analyzed. Median survival was significantly 
better for women than for men (Table 4). Survival decreased 
with increasing age and poorer PS. Median survival, 
1-year survival and 2-year survival were 10 months, 42% and 
21% in 2000, respectively, and increased to 12 months, 51% 
and 27% in 2007, respectively. However, this change in sur-
vival over time was not statistically significant. For patients 
with Stage IIIA NSCLC median survival increased from 
13 months in 2000 to 15 months in 2007 (p = 0.06), and for 
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those with Stage IIIB NSCLC from 7 months to 9 months 
(p = not significant).
Patients who had surgery combined with other 
therapies had a median survival of 34 months (95% CI 27.5–
40.5 months), curative surgery alone 27 months (95% CI 
19.6–34.3 months), curative RT and chemotherapy 24 months 
(95% CI 20.6–27.4 months), and curative RT alone 13 months 
(95% CI 8.3–17.7 months). Palliative treatment resulted in a 
median survival of 8 months (95% CI 7.5–8.5 months) and 
BSC 5 months (95% CI 3.9–6.1 months) (p < 0.001).
On multivariable analysis, factors predictive of improved 
survival were female sex, younger age, better PS, Stage IIIA 
disease, and later period of diagnosis (Table 5). Pathology was 
not an independent predictor of survival.
DISCUSSION
Stage III NSCLC is a diverse disease that can be 
challenging to treat because the population it occurs in is 
elderly, often with associated smoking-related comorbidities. 
Although there are many trials of treatment in NSCLC, these 
are often limited to younger, fitter patients, and the applicabil-
ity of results to the general lung cancer population is poorly 
studied. To gain a better understanding of treatment patterns 
at a population level, we retrospectively reviewed the man-
agement of patients with confirmed Stage III NSCLC. This 
cohort of patients was mainly staged without positron emis-
sion tomography (PET) scans. PET scanning only became 
available in British Columbia in 2005 and was limited to one 
center with limited capacity, so would only have been per-
formed in a minority of patients in the study population.
This cohort was similar to other Western lung cancer 
populations in terms of age and PS.12–15 The proportion of 
women was similar to other North American populations 
but more than that described in Australia, New Zealand, 
Scotland, and the Netherlands.6,12–14 Pathology distribu-
tion showed that 31% of the patients were diagnosed with 
NSCLC without any further pathological subtyping. This 
proportion increased significantly from 1% in 2000 to 47% 
in 2007. It is possible that there was a change in the method 
of tissue collection with greater reliance on fine needle 
aspiration biopsy and interventional radiologist biopsies in 
the latter years. Information on the nature of biopsies taken 
was not collected. Nevertheless, this group of unspeci-
fied NSCLC is greater than that described in the United 
States.13 During the study era, pathological subtyping was 
not a determinant of treatment. However, it is now well 
recognized that different pathological subtypes are associ-
ated with differential response rates to systemic therapies.16 
The International Association for the Study of Lung Cancer 
now has a detailed classification of adenocarcinoma, which 
includes molecular subtyping.17 These recommendations 
TABLE 4. Univariable Overall-Survival Estimates for Study 
Cohort
n
Median 
Survival in 
Months  
(95% CI)
3 Year 
Survival 
(%±SE) P
Sex
 Male 1183 9 (8.3–9.7) 11.6 ± 1.0
 Female 970 12 (11.1–12.9) 17.8 ± 1.3 <0.001
Age (yrs)
 <50 145 15 (11.6–18.4) 21.8 ± 3.6
 50–64 647 13 (11.8–14.2) 17.9 ± 1.6
 65–79 1085 10 (9.2–10.8) 13.4 ± 1.1
 ≥80 276 7 (5.8–8.2) 6.3 ± 1.5 <0.001
ECOG PS
 0–2 1369 13 (12.2–13.8) 18.1 ± 1.1
 3–4 392 4 (3.4–4.6) 1.9 ± 0.7
 Unknown 392 9 (7.7–10.3) 13.7 ± 1.8 <0.001
Year
 2000 275 10 (8.5–11.5) 12.6 ± 2.1
 2001 233 8 (6.7–9.3) 10.3 ± 2.1
 2002 258 10 (8.3–11.6) 15.5 ± 2.3
 2003 249 11 (9.1–12.9) 15.0 ± 2.3
 2004 269 11 (9.3–12.7) 13.7 ± 2.2
 2005 283 11 (9.5–12.5) 15.9 ± 2.2
 2006 275 11 (9.3–12.7) 16.2 ± 2.4
 2007 311 12 (10.3–13.7) 14.7 ± 2.2 NS
Stage
 IIIA 1064 13 (12.1–13.9) 18.9 ± 1.3
 IIIB 1089 8 (7.3–8.7) 10.4 ± 1.0 <0.001
Pathology
 Squamous 661 10 (9.0–11.0) 12.5 ± 1.3
 Adenocarcinoma 589 13 (11.8–14.1) 19.2 ± 1.7
 Large-cell 106 9 (7.2–10.8) 15.3 ± 3.6
 NSCLC other 797 10 (9.1–10.9) 12.2 ± 1.2 <0.001
SE, standard error; ECOG PS, Eastern Cooperative Oncology Group performance 
status; NS, not significant; NSCLC, non–small cell lung cancer.
TABLE 5. Multivariable Analysis of Factors Predictive of Survival
Variable Odds Ratioa 95% CI P
Sex
 Male 1 0.03
 Female 0.73 0.56–0.97
Age (yrs)
 <50 1 <0.0001
 50–64 1.39 0.86–2.25
 65–79 2.01 1.30–3.32
 80+ 4.50 2.45–9.00
ECOG PS
 0–2 1 <0.0001
 3–4 4.47 2.45–8.14
 Unknown 0.97 0.68–1.38
Stage
 IIIA 1 <0.0001
 IIIB 1.93 1.46–2.56
Year diagnosed
 2000–2003 1
 2004–2007 0.45 0.34–0.61 <0.0001
ECOG PS, Eastern Cooperative Oncology Group performance status; CI, confidence 
interval.
aOdds ratio > 1 predicts for higher risk of death.
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need to be implemented  to direct appropriate selection of 
therapies for patients.
In this contemporary population of patients with Stage 
III NSCLC, the most common treatment was RT alone, given 
in just over half of all patients. This is greater than in the 
American and Australian populations (Table 6).12,13 The use 
of surgery or surgery combinations was similar to that docu-
mented in Australia but less than that in the United States. 
Chemotherapy as a single modality was used less frequently. 
In combination with RT, it was used more often than in 
Australia but less than in the United States. However, patients 
in the current study were the most likely to receive some form 
of active treatment for their lung cancer, with only 10.5% 
receiving BSC alone compared to 18.5% in the United States 
and 28% in Australia.
A selection bias in patients referred to BCCA may 
account for some of the differences regarding surgery and 
BSC. During the study period, 63% of all patients diagnosed 
with lung cancer were referred to BCCA. The true propor-
tion receiving either BSC or surgery alone would have been 
higher if all diagnoses of lung cancer in the province were 
included. A previous study in British Columbia has shown 
that in 2002, the crude referral rate of lung cancer patients 
to BCCA within 6 months of diagnosis was 67%.18 In this 
study, surveys were sent to family physicians enquiring about 
stage and PS. The nonreferred group was characterized by 
two groups of patients, those with localized disease and good 
PS who received surgery, and those with metastatic disease 
and poor PS who received BSC. Only 28% of the nonreferred 
patients had Stage III NSCLC, therefore, of all lung cancer 
patients, an additional 10% of Stage III cases may have been 
excluded from our analysis. Given that all RT in the province 
is delivered at BCCA centers, none of these patients would 
have received initial RT, although they may have been treated 
with surgery or chemotherapy in the community.
Differences in population characteristics may partly 
explain the differences in patterns of treatment. Eighty per-
cent of the Australian population and 72% of the American 
population had a comorbidity, which may have influenced 
treatment. This variable was not recorded in the current popu-
lation although there is no reason to think this would be dis-
similar across Western populations.
The main difference between the Canadian and other 
populations was the less frequent use of chemotherapy. Meta-
analyses published in 1995 and updated in 2002 showed that the 
addition of chemotherapy to RT or to BSC resulted in improved 
survival.19,20 Surveillance, Epidemiology and End Results data 
from 2001 show that 58.4% of patients with Stage III NSCLC 
received chemotherapy as part of initial treatment.13 This com-
prised 11.5% receiving chemotherapy alone, 26.2% with RT, 
and 10.7% with surgery. The BCCA guidelines of 2000 recom-
mended chemoradiotherapy for nonsurgical patients with good 
PS and minimal weight loss. Although the overall use of chemo-
therapy was lower than that in other populations, the majority 
of patients (79%) receiving curative RT also received chemo-
therapy, greater than the proportion (60%) described in a U.S. 
pattern of care study.21 During the period of the study, the pro-
portion receiving chemoradiotherapy doubled, and that receiv-
ing concurrent chemoradiotherapy trebled.
The BCCA guidelines also recommended palliative 
chemotherapy over BSC in patients of good PS not suitable 
for curative treatment. However, the incorporation of pallia-
tive chemotherapy for Stage III NSCLC in British Columbia 
has been less than in other jurisdictions. Patient comorbidi-
ties may have precluded treatment although we would expect 
this to be similar across affluent Western populations. Patient 
preferences may have been a factor. In metastatic lung cancer, 
only 22% of patients would have chemotherapy for a survival 
benefit of 3 months although 68% would choose it for symp-
tom relief without any survival benefit.22 In addition, palliative 
RT provides symptomatic relief for chest symptoms without 
the systemic toxicity of chemotherapy.23 Pragmatic clinicians 
may be less likely to incorporate treatment associated with a 
modest survival benefit into clinical practice.
A lack of access to medical oncologists may also have 
resulted in the lower chemotherapy use. We do not have data 
regarding the proportion of the study population who saw 
a medical oncologist. A review of SEER data showed that 
36% of patients who did not receive chemotherapy for their 
advanced lung cancer were not seen by a medical oncologist.24 
During the study period, there were unfilled medical oncology 
positions in British Columbia. Although this may have created 
delay in access to a medical oncologist, it is unlikely to have 
served as an absolute barrier for referral. At all BCCA centers, 
the medical and radiation oncologists work closely together, 
and patients are triaged to see either or both subspecialties at 
the time of initial referral by a triaging physician, who may be 
a clinician from either specialty.
In this population-based cohort, 38% of patients 
with Stage IIIA NSCLC, 22.7% of patients with Stage IIIB 
NSCLC, and 28.5% overall received treatment with curative 
intent. With the staging system in use during the period of 
the study, patients with malignant pleural effusion would have 
been included in the Stage IIIB group, although they were not 
candidates for curative treatment. The new staging system, 
TNM 7th edition now classes these patients as having Stage 
IVa disease as their prognosis is worse than that of patients 
having Stage IIIB disease on the basis of T4 or N3 characteris-
tics.25 Other population-based studies have also documented a 
low proportion of patients suitable for treatment with curative 
TABLE 6. Comparison with Other Population-Based Studies of 
Utilization of Different Treatments in Stage III NSCLC (%)
USA 200113
n = 11,263
New South 
Wales, Australia 
2001–200212
n = 308
British 
Columbia, 
Canada 
2000–2007  
N = 2153
Surgery alone 6.6 4 4.5
Radiotherapy alone 16.5 31 51.5
Chemotherapy alone 11.5 11 4
Surgery combination 10.7 7 7.1
Radiotherapy and  
 chemotherapy
36.2 19 22.4
Best supportive care 18.5 28 10.5
NSCLC, non–small-cell lung cancer.
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intent. In New Zealand in 2004, Stevens et al.14 found that 
11.5% of Stage III patients received curative treatment. 
In Australia from 2001 to 2002, 26% of Stage III patients 
received a combination treatment with two or three treatment 
modalities in 2001 to 2002, presumably treated with curative 
intent, although this does not include patients who may have 
received curative RT alone.12
RT with curative intent was only given in 16.9% of all 
patients or 19.1% of all nonsurgical patients. The respective 
figures for chemotherapy combined with RT were 13.3% and 
15.1%. De Ruysscher et al.6 calculated that 41% of inoperable 
Stage III patients in the Netherlands would be eligible for con-
current chemoradiotherapy on the basis of age or comorbidity. 
In a study of 276 consecutive Dutch patients treated between 
2004 and 2005, Ouwens et al.26 found that 39% of Stage III 
patients were treated with chemoradiotherapy. These figures are 
more than double of that seen in the current population, sug-
gesting that patient and clinician factors may be responsible.
The characteristics of patients enrolled in clinical trials 
often do not reflect those of the general lung cancer popula-
tion, who tend to be older, with comorbidities and a range of 
PS. Thus, selecting patients for combined treatment can be 
difficult as results often have to be extrapolated to a patient 
who would be ineligible for trial entry. Large tumor volume 
and compromised respiratory function are also factors that 
have to be taken into consideration but are poorly reported in 
clinical trials. Tumor volume alone, however, does not neces-
sarily contraindicate a radical RT approach.27
Clinician factors may also explain the differences in 
treatment. The difference in the use of chemoradiotherapy 
between the Dutch and Canadian populations may be because 
of different attitudes of oncologists in British Columbia. 
However, attitudes are changing. A survey of Canadian radia-
tion oncologists in 2010 found that 61% of respondents would 
recommend radical chemoradiotherapy for a patient with a 
bulky Stage IIIB lung cancer compared to only 31% in survey 
from 1993.28 Clinicians who see a smaller volume of lung can-
cer patients (<10 per year) are also less likely to recommend 
chemoradiotherapy for unresectable Stage III NSCLC.29
The utilization of RT was similar to that predicted by 
models of optimal utilization, showing that British Columbian 
residents who were referred to BCCA were likely to receive RT 
as indicated. Even if we adjust our RT utilization estimate to 
account for the potential additional 10% of non-referred Stage 
III cases, the overall RT utilization rate in the province remains 
high at 71%, comparable to model estimates. However, chemo-
therapy utilization was appreciably lower than that predicted. It 
is possible that the model overestimates the optimal utilization 
of chemotherapy as factors that influence the decision for che-
motherapy, such as patient comorbidities and preference, are 
not taken into account. Nevertheless, this population was less 
likely to receive chemotherapy than contemporary populations 
in the United States, Australia, and the Netherlands.12,13,26
The treatment patterns over time show increasing use of 
curative therapies particularly radical RT combined with che-
motherapy. The main increase was seen from 2001 to 2003, 
which predated the availability of PET scanning from 2005 
onward. Use of PET scans to stage patients could potentially 
lead to stage migration with improved survival as a result of 
better patient selection rather than treatment. There was a 
gradual increase in survival throughout the whole study period 
rather than after 2005 alone, suggesting a treatment effect. 
However, this modest 2-month improvement in survival did 
not reach statistical significance.
The survival seen in this population according to treat-
ment modality is comparable to, if not better than, random-
ized trials reported in the literature.30 The median survival of 
34 months for patients receiving surgery combination treat-
ment is greater than the 16 months reported in the European 
Organisation for Research and Treatment of Cancer study9 
and the 24 months reported in an Intergroup study.10 Similarly, 
patients receiving curative chemoradiotherapy had a superior 
survival of 24 months compared to the 18 months and 22 
months seen in the EORTC and Intergroup studies, respec-
tively.9,10 These results support the opinion that definitive tho-
racic irradiation delivered concurrently with chemotherapy is 
a model of curative treatment for Stage III NSCLC, which has 
not been seriously challenged.
This study reports on patterns of care for patients with 
Stage III NSCLC treated in a contemporary time period. 
The management of lung cancer continues to evolve, and 
the applicability of the results to current practice need to be 
interpreted in light of the new lung cancer staging sys-
tem adopted in 2010 and the use of fluorodeoxyglucose-
PET scans to routinely stage patients. The main impact 
of the new staging system for the study cohort would be to 
upstage those with malignant pleural effusions to Stage IVA 
disease. We know that at least 5% of patients with Stage 
IIIB NSCLC in this study would fall into this category, but 
this can be as high as 33% evaluated from an audit of 105 
patients with Stage IIIB NSCLC seen in south-west Sydney, 
Australia over the same time period as this study (unpub-
lished data, S. Vinod, January 2011). Similarly, the increased 
sensitivity of staging with FDG-PET would upstage some 
of these patients to Stage IV disease, and potentially 
downstage a few as well. The effect of both these factors is 
likely to increase the rate of utilization of curative treatment 
and improve outcomes of the study cohort by excluding 
incurable patients. The comparisons made were with other 
similar studies that used the same staging system mostly in 
the pre-PET era. The adoption of evidence-based prac-
tice from clinical trials at the population level is not often 
reported. This study shows a shift in patterns of care over time 
resulting in increased use of curative treatment, particularly 
chemoradiotherapy, which translated into modest improvement 
in survival, although this did not reach statistical significance.
CONCLUSION
To the best of our knowledge, this is the largest report 
on the outcomes of a population-based cohort with Stage III 
NSCLC. Almost a third of patients had no pathological sub-
typing of their cancer, a process that is becoming increasingly 
important in the era of targeted therapies and recognized dif-
fering efficacy of systemic agents according to pathology. 
There was an increase in the use of curative treatment over 
time, which may account for the modest improvement seen 
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in survival. The use of RT was in keeping with the estimates 
from published models. However, the use of chemotherapy 
remains lower than that in other contemporary populations. 
Further increases in the proportion receiving curative RT can 
be facilitated by the technological advances in RT, which 
allow better target definition and reduced treatment toxicity. 
Improvements in supportive care may also allow more patients 
to receive combined modality treatment. Patients with Stage 
III NSCLC account for up to a third of the NSCLC popula-
tion, and improving the use of curative treatment in this group 
is likely to impact overall survival for the whole population.
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